Biogen Inc. (BIIB)
Biogen is a biotechnology company focused on developing complex medicines for people living with serious neurological and neurodegenerative diseases.
Is Biogen Inc. a good stock for a UK beginner?
The honest version: Biogen is a biotechnology company focused on developing complex medicines for people living with serious neurological and neurodegenerative diseases.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Breakthrough success in the company's research pipeline.
Failure of key research projects to reach the market.
What does Biogen Inc. do?
Biogen spends its time researching and selling treatments for conditions like multiple sclerosis and, more recently, Alzheimer's disease. Those specialist drugs, sold to healthcare providers and hospitals around the world, are where the earnings come from. Two things really matter here: how readily doctors adopt their new Alzheimer's treatments, and whether they can launch new medicines to replace older ones losing patent protection.
On our factor screen it looks strongest on momentum and quality, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 3% over the year
- !High P/E of 37 - big growth is already priced in
- Momentum screens high (72/100)
- High profit margins on products
- Specialised focus on difficult-to-treat diseases
- Lower price volatility compared to the broader market
- Growth screens low (12/100)
- Income screens low (16/100)
- High uncertainty inherent in drug development
- Potential for regulatory bodies to reject new treatments
- Pressure from generic drug manufacturers
What do Biogen Inc.'s numbers mean?
How much money does Biogen Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Biogen Inc. pay a dividend?
No - Biogen Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Biogen Inc. report earnings, and how did recent quarters go?
Biogen Inc. is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-29 | $2.03 | $3.60 | Beat +77% |
| 2026-04-29 | $2.89 | $3.57 | Beat +24% |
| 2026-02-06 | $1.62 | $1.99 | Beat +23% |
| 2025-10-30 | $3.88 | $4.81 | Beat +24% |
| 2025-07-31 | $3.88 | $5.47 | Beat +41% |
| 2025-05-01 | $2.95 | $3.02 | Beat +2% |
Across the last 6 quarters here, Biogen Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Biogen Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Biogen Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins on products
- Specialised focus on difficult-to-treat diseases
- Lower price volatility compared to the broader market
- No dividend payments for income-focused investors
- Heavy reliance on a small number of key drugs
- Slow overall revenue growth
- High uncertainty inherent in drug development
- Potential for regulatory bodies to reject new treatments
- Pressure from generic drug manufacturers
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a late-stage clinical trial
- A significant change in government healthcare reimbursement policies
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.